NASOPHARYNGEAL CANCER
Clinical trials for NASOPHARYNGEAL CANCER explained in plain language.
Never miss a new study
Get alerted when new NASOPHARYNGEAL CANCER trials appear
Sign up with your email to follow new studies for NASOPHARYNGEAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could less be more? shorter immunotherapy course tested for head and neck cancer
Disease control Not yet recruitingThis study compares a shorter versus longer course of the immunotherapy drug tislelizumab, given alongside standard chemoradiotherapy, for people with advanced nasopharyngeal cancer. About 418 adults aged 18 to 65 with stage T4N1 or T1-4N2-3 disease will be randomly assigned to r…
Matched conditions: NASOPHARYNGEAL CANCER
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New drug cocktail aims to shrink tough head and neck cancers
Disease control Not yet recruitingThis study tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemoradiation can better shrink or control high-risk nasopharyngeal cancer. About 514 adults with advanced, newly diagnosed disease will be split into two groups to compare the new …
Matched conditions: NASOPHARYNGEAL CANCER
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug cocktail aims to stop High-Risk throat cancer in its tracks
Disease control Not yet recruitingThis phase 3 trial tests whether adding anlotinib (a targeted therapy) to standard chemoradiotherapy and immunotherapy can improve outcomes for people with high-risk nasopharyngeal cancer. About 412 adults aged 18-65 with advanced, non-spreading throat cancer will be randomly ass…
Matched conditions: NASOPHARYNGEAL CANCER
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC